🇺🇸 FDA
NDI pending (2022 NDIN ruling withdrawn 2023 · marketed as dietary supplement under existing DSHEA)
NMN (β-Nicotinamide Mononucleotide)
Also known as: β-NMN · Nicotinamide Mononucleotide
Mechanism of action
- NAD+ salvage pathway substrate
- Sirtuin family co-substrate
- Mitochondrial biogenesis
Molecular + tissue targets
- NAD+ pool
- Sirtuins (SIRT1-7)
- CD38
- Mitochondria
Dosage range
250-1000 mg/day (functional benefit RCTs at 250 mg/day · safety to 1250 mg/day for 4 weeks)
Safety notes
No adequate human data in pregnancy/lactation/ART · TGA permissible upper 500 mg/day · long-term safety beyond 12 months not established
Cross-market regulatory status
🇪🇺 EFSA
Novel Food classification (no authorized claim)
🇧🇷 ANVISA
RDC 243/2018 dietary supplement framework · IN 28/2018 alegações funcionais not authorized
Authorized claims · verbatim (1)
Direct quotes from each jurisdiction's framework · never paraphrased · with framework reference and conditions of use.
🇦🇺 TGA · 1 claim
TGA Permissible Ingredients Determination (No. 4) 2025 · effective 10 December 2025
Nicotinamide mononucleotide is a permissible ingredient for Australian Listed Medicines (AUST L) · maximum daily dose 500 mg
Conditions: Listed medicine (AUST L) framework · maximum daily dose 500 mg · duration of use 12 weeks or less · adults only · NOT for pregnant or lactating women · no specific health claim authorized · 2-year market exclusivity period Dec 2025 - Dec 2027 (SyncoZymes)
Authorized 2025-12-10
Common use cases
- healthy aging
- metabolic surrogate
- athletic recovery
- NAD+ decline
Cross-reference
Health goals: longevity stack athletic performance cognitive support heart health
Lifestyles: senior 60 plus high stress intermittent fasting
Full dossier: /ingredients/nmn/
Machine-readable JSON: /api/nc/nmn.json